search
Back to results

Lumbar Erector Spinae Plane Block for Back Surgery (LUMBES)

Primary Purpose

Pain, Postoperative, Anaesthesia, Surgery

Status
Recruiting
Phase
Phase 3
Locations
Belgium
Study Type
Interventional
Intervention
Erector spinae plane block
Levobupivacaine 0,25%
spine fusion
NaCL 0,9%
Sufentanil
propofol
Rocuronium Bromide
sevoflurane
paracetamol
Ketorolac
morphine pca
Dexamethasone
Morphine
Sponsored by
Dr M. B. Breebaart
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Postoperative

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • - Patients scheduled for 1-2 level posterior lumbar interfusion surgery in AZ KLINA Hospital or University of Antwerp Hospital (UZA) after approval of Ethical Committee until all required patients are included
  • American Society of Anesthesiologist (ASA) score of 1 - 3
  • Age 18 - 75 year
  • Normal liver and renal function

Exclusion Criteria:

  • Age <18 years or mentally incompetent
  • BMI < 16 or BMI > 35
  • Allergy to one or more substances of the study medication (= levobupivacaine, dexamethasone, propofol, sufentanil, rocuronium, ketorolac, morphine, ketamine, DHBP, ondansetron, alizapride)
  • Chronic strong opioid use (>3 intakes per week)

Sites / Locations

  • AZ KLinaRecruiting
  • University Hospital AntwerpRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

ESB group

SHAM group

Arm Description

Erector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane. Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea.

Erector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea.

Outcomes

Primary Outcome Measures

24 hour morphine consumption
total milligrams (0-150) of morphine used in the first 24 hours after surgery, extracted out of the pca pump data.

Secondary Outcome Measures

Intraoperative sufentanyl requirement (
total Intravenous administered sufentanyl in micrograms during surgery(10-100)
Morphine consumption 72 hours
total milligrams of morphine used in 72 hours after surgery (0-450), extracted out of the pca pump data
NRS pain scores
Numeric rating scale pain score (in numbers) and rest (0= no pain10 =worst thinkable pain)
Quality of recovery score (QoR-40)
score in numbers of mental and psychological well being scored by list of questions (minimal score 20-maximum score 200). A high score indicates a better/faster recovery, and is inversely correlated with hospital stay
time to mobilisation to chair
movements (mobilisation to chair) in hours after surgery
time to 20 meter walking
movement 20 meter walking in hours after surgery

Full Information

First Posted
November 13, 2018
Last Updated
August 4, 2022
Sponsor
Dr M. B. Breebaart
search

1. Study Identification

Unique Protocol Identification Number
NCT03825198
Brief Title
Lumbar Erector Spinae Plane Block for Back Surgery
Acronym
LUMBES
Official Title
A Prospective Randomized Double Blind Trial of the Efficacy of a Bilateral Lumbar Erector Spinae Block on the 24h Morphine Consumption After Posterior Lumbar Interbody Fusion Surgery.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2019 (Actual)
Primary Completion Date
December 15, 2023 (Anticipated)
Study Completion Date
December 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dr M. B. Breebaart

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Title: A prospective randomized double blind trial of the efficacy of a bilateral lumbar erector spinae block on the 24 h morphine consumption after posterior lumbar interbody fusion surgery. Objectives: The primary objective is to study the influence of a bilateral erector spinae block on 24h morphine consumption. Endpoint: The primary endpoint is the 24 h morphine consumption in mg. Secondary endpoints are intraoperative sufentanil requirement, total morphine during first 72 postoperative hours, NRS pain scores in rest and defined movement (moving to chair) at regular time intervals and Quality of Recovery 40 score (QoR-40) at fixed time intervals day 1 and 3 postoperatively Population: Patients undergoing posterior lumbar interbody fusion ranging 1 - 3 levels Phase 3 Number of sites Enrolling participants: University Hospital Antwerp &AZ KLINA Brasschaat Description of study agent: Bilateral erector spinae block: each block contains 20 ml levobupivacaine 0.25% + 5 mcg/ml epinephrine Study duration Until the required study population is met Participant duration 72 hours
Detailed Description
In this prospective randomized double blind placebo controlled clinical trial we would like to assess the efficacy of a bilateral lumbar erector spinae block on the 24h morphine consumption after posterior lumbar interbody fusion surgery. Patients scheduled for 1-2 level PLIF surgery will be recruited in AZ KLINA in Brasschaat and the University Hospital Antwerp in Edegem. The study contains two arms. Subjects will be randomly allocated to an erector spinae block group or the sham block group (placebo). Stratified randomization will be done according to gender, levels of surgery and site online with Q minim.The study medication will be prepared in identical premade syringes and numbered according to a computer generated block randomization list (1:1 ratio ESB:sham). Subjects will be assigned consecutive numbers upon inclusion to the study and receive the study medication from the corresponding numbered syringes. The study medication in syringes for injection will be prepared by an anesthesiologist neither involved in the study nor in the care of the patient, before handing it over to the investigators. The ESB-group will receive 20 ml Chirocaine 0,25%. The sham block group medication will receive 20 ml Nacl0,9%. The levobupivacaine and saline 0.9% are identical in appearance. All investigators, staff and patients will be blinded to the treatment groups. Epinephrine is added to the placebo block in order to prevent unblinding by increased heart rate or blood pressure. Unmasking will not occur until statistical analysis is complete. Patients in the erector spinae block group will receive a bilateral ESB block with an injectate containing 20 ml of levobupivacaine 0.25% in each puncture. Patients allocated to the sham group receive a bilateral ESB block with each injectate containing 20 mL of NaCl 0.9% . The blocks will be performed by experts in the field of ultrasound guided locoregional anaesthesia namely dr D. van Aken, dr L. Sermeus and dr M.B. Breebaart who are also teachers for the BARA (Belgian Association of Regional Anaesthesia). The blocks will be performed preoperatively in a separate block room with ultrasound after placement of an iv line and application of standard monitoring (ECG, NIBP, saturation). The blocks will be placed as described by Chin et al. modified for lumbar level.8 First, the patient will be placed in the lateral or sitting position. A curve array probe or a high frequency linear probe, depending on the BMI of the patient, will be placed in a longitudinal position 2-3 cm lateral of the vertebral column. The transverse processes of the vertebrae at the (mid) level of surgery, the erector spinae muscle and the psoas muscle are identified. In case of two level surgery the transverse process of the upper level will be considered as the preferred target. Depending on the depth a 5 or 8 cm 22 G ultrasound needle (Pajunk) will be inserted with an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, 20 ml of the study medication will be injected behind the erector spinae muscle. The same procedure will be repeated on the contralateral side. General anesthesia will then be induced in a standardized way with propofol 2-3mg/kg, sufentanil 15mcg and rocuronium 0.5mg/kg. After tracheal intubation anesthesia will be maintained with sevoflurane and intraoperative analgesia with sufentanil. The dosages of these agents will be determined at the discretion of the anesthesiologist. At the end of surgery patients will receive acetaminophen 1g IV, ketorolac (Taradyl, CSP Benelux) 0.5 mg/kg (max. 30 mg) IV and a morphine loading dose (0.1 mg/kg) IV to manage postoperative pain. Patients will be extubated in the operating theatre and admitted to the post anesthesia care unit (PACU). Postoperative pain in the PACU and on the ward will be treated with acetaminophen 1g IV round the clock (4 times daily) and by a patient controlled intravenous analgesia pump (PCIA) with morphine at a concentration of 1 mg/ml and dehydrobenzperidol (DHBP) 0.05 mg/ml. The PCIA will be set using a standardised protocol: no background administration of morphine, a bolus dose of 1.5 mL morphine with a lock-out interval of 8 minutes and an hourly limit of 7.5 mg. If pain management on the PACU is inadequate (NRS > 3) additional boli of 1 mg morphine IV will be administered with the total additional dose of morphine limited to 0.15mg/kg morphine. In case NRS is still > 3 an IV ketamine (Ketalar, Pfizer) bolus (0.2 mg/kg) will be given. All patients receive dexamethasone 5mg IV as postoperative nausea and vomiting (PONV) prophylaxis. If needed, this will be supplemented by ondansetron 4mg IV and if still insufficient with alizapride 50mg IV. Other study endpoints will be retrieved from the patient data management systems The morphine consumption during the first 24 hours postoperatively will be extracted out of the PCIA pump. The total morphine dose requirement during the first 72 postoperative hours will also be extracted out of the PCIA pump. Pain scores at rest will be assessed with the numeric rating scale (NRS, 0=no pain 10= worst imaginable pain) and tested at regular time intervals: at the time of inclusion, at the PACU (T0 = arrival at Post Anesthesia Care Unit, T+15min, T+30min) and ward (twice daily- morning and evening until postoperative day 3) Pain scores during defined movement (first moving to chair and upright sitting) will be examined. Time to first mobilization in chair (in hours since T0) and time to first walk of twenty meters (in hours since T0) will be noted in the patients study diary. The quality of recovery 40 score (QoR-40) will be calculated out of a series of questions patients are required to answer at day 1 and 3 postoperatively. The QoR-40 is a widely used and extensively validated measure of quality of recovery. It is a 40-item questionnaire on quality of recovery from anesthesia, that has been shown to measure health status after surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative, Anaesthesia, Surgery, Nerve Block, Anesthesia, Local, Back Pain, Spinal Fusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
double blind randomised
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The medication for the sham block with NaCl or the local anaesthetic will be prepared by an independent medical caregiver who has no connection with the patient. The anaesthetics performing the block, the patient and the observation nurses/doctors collecting the data are masked. The solutions used are not distinguishable from each other.
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ESB group
Arm Type
Active Comparator
Arm Description
Erector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane. Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea.
Arm Title
SHAM group
Arm Type
Sham Comparator
Arm Description
Erector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea.
Intervention Type
Procedure
Intervention Name(s)
Erector spinae plane block
Other Intervention Name(s)
Locoregional anaesthesia
Intervention Description
Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
Intervention Type
Drug
Intervention Name(s)
Levobupivacaine 0,25%
Other Intervention Name(s)
chirocaine
Intervention Description
20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
Intervention Type
Procedure
Intervention Name(s)
spine fusion
Intervention Description
fusion of lumbar vertebral body on 1 or two levels
Intervention Type
Drug
Intervention Name(s)
NaCL 0,9%
Intervention Description
20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
Intervention Type
Drug
Intervention Name(s)
Sufentanil
Other Intervention Name(s)
sufenta
Intervention Description
opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
Intervention Type
Drug
Intervention Name(s)
propofol
Intervention Description
induction agent for general anaesthesia ( 2-3 mg/kg)
Intervention Type
Drug
Intervention Name(s)
Rocuronium Bromide
Other Intervention Name(s)
sermon
Intervention Description
muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
Intervention Type
Drug
Intervention Name(s)
sevoflurane
Intervention Description
inhalation aesthetic used for the maintenance of general anaesthesia
Intervention Type
Drug
Intervention Name(s)
paracetamol
Intervention Description
postoperative drug for analgesia ( 1 gram 4/day)
Intervention Type
Drug
Intervention Name(s)
Ketorolac
Intervention Description
non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
Intervention Type
Drug
Intervention Name(s)
morphine pca
Other Intervention Name(s)
patient controlled analgesia
Intervention Description
postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Other Intervention Name(s)
aacidexam
Intervention Description
drug given during general anaesthesia to prevent postoperative nausea
Intervention Type
Drug
Intervention Name(s)
Morphine
Intervention Description
loading dose morhine 0,1 mg/kg at the end of surgery
Primary Outcome Measure Information:
Title
24 hour morphine consumption
Description
total milligrams (0-150) of morphine used in the first 24 hours after surgery, extracted out of the pca pump data.
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Intraoperative sufentanyl requirement (
Description
total Intravenous administered sufentanyl in micrograms during surgery(10-100)
Time Frame
2-5 hours
Title
Morphine consumption 72 hours
Description
total milligrams of morphine used in 72 hours after surgery (0-450), extracted out of the pca pump data
Time Frame
72 hours
Title
NRS pain scores
Description
Numeric rating scale pain score (in numbers) and rest (0= no pain10 =worst thinkable pain)
Time Frame
at regular intervals and defined movement until 72 hours after surgery
Title
Quality of recovery score (QoR-40)
Description
score in numbers of mental and psychological well being scored by list of questions (minimal score 20-maximum score 200). A high score indicates a better/faster recovery, and is inversely correlated with hospital stay
Time Frame
day 1 and day 3 postoperatively
Title
time to mobilisation to chair
Description
movements (mobilisation to chair) in hours after surgery
Time Frame
8-72 hours
Title
time to 20 meter walking
Description
movement 20 meter walking in hours after surgery
Time Frame
8-72 hours
Other Pre-specified Outcome Measures:
Title
expected preoperative pain score (NRs°
Description
Numeric rating scale pain score (in numbers). pain that people expect before they have surgery.
Time Frame
before surgery ( moment of inclusion)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Patients scheduled for 1-2 level posterior lumbar interfusion surgery in AZ KLINA Hospital or University of Antwerp Hospital (UZA) after approval of Ethical Committee until all required patients are included American Society of Anesthesiologist (ASA) score of 1 - 3 Age 18 - 75 year Normal liver and renal function Exclusion Criteria: Age <18 years or mentally incompetent BMI < 16 or BMI > 35 Allergy to one or more substances of the study medication (= levobupivacaine, dexamethasone, propofol, sufentanil, rocuronium, ketorolac, morphine, ketamine, DHBP, ondansetron, alizapride) Chronic strong opioid use (>3 intakes per week)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
margaretha breebaart, MD PhD
Phone
003238213865
Email
margaretha.breebaart@uza.be
First Name & Middle Initial & Last Name or Official Title & Degree
Olivier defre, MD
Phone
003238213042
Email
olivier.defre@uza.be
Facility Information:
Facility Name
AZ KLina
City
Brasschaat
State/Province
Antwerp
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David van Aken, MD
Phone
0032-3-6505110
Email
David.Van.Aken@klina.be
Facility Name
University Hospital Antwerp
City
Antwerp
ZIP/Postal Code
2650
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Margaretha Breebaart, MD, PhD
Phone
003238213042
Email
margaretha.breebaart@uza.be
First Name & Middle Initial & Last Name & Degree
Olivier Defre, MD
Phone
003238213042

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31315670
Citation
Breebaart MB, Van Aken D, De Fre O, Sermeus L, Kamerling N, de Jong L, Michielsen J, Roelant E, Saldien V, Versyck B. A prospective randomized double-blind trial of the efficacy of a bilateral lumbar erector spinae block on the 24h morphine consumption after posterior lumbar inter-body fusion surgery. Trials. 2019 Jul 17;20(1):441. doi: 10.1186/s13063-019-3541-y.
Results Reference
derived

Learn more about this trial

Lumbar Erector Spinae Plane Block for Back Surgery

We'll reach out to this number within 24 hrs